EVOKE PHARMA INC EVOK
COM · Common Stock · CUSIP 30049G302
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Implied quarter-end price ≈ $2.60.
Trends to Q2 2025
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2024 | 13 |
| Q4 2024 | 9 |
| Q1 2025 | 11 |
| Q2 2025 | 11 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2024 | 2 | 6 |
| Q1 2025 | 4 | 2 |
| Q2 2025 | 3 | 2 |
Biggest buyers
| Tower Research Capital LLC (TRC) | Added | +1.8k |
| FMR LLC | New | +301 |
| BANK OF AMERICA CORP /DE/ | Added | +1 |
Biggest sellers
| BRC Group Holdings, Inc. | Sold out | -20.0k |
| CITADEL ADVISORS LLC | Reduced | -12.3k |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
Klein Roger M.
13D · may seek influence
new · filed 2025-11-12
Stated purposeOn November 4, 2025, Mr. Klein acquired, or in his capacity as trustee caused the Krieger Charitable Trust (the "Charitable Trust") to acquire, all 163,000 shares of Common Stock of the Issuer currently owned by the Reporting Persons (the "Klein Shares"). This acquisition came after the Issuer announced in a Current Report on Form 8-K (the "Merger 8-K") filed with the U.S. Securities and Exchange Commission on November 4, 2025, that on November 3, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger") with QOL Medical, LLC, a Delaware limited liability company ("Parent"), and certain of its affiliates (together with Parent, "QOL"), pursuant to which QOL will commence a tender offer (the "Offer") to acquire all of the outstanding shares of Common Stock for $11.00 in ca… Full filing |
10.5% |
Fell to 5% or below in the last year: Nantahala Capital Management, LLC (0.0%, 2025-12-19), MORGAN STANLEY (0.0%, 2025-12-05)
Holders, Q2 2025
| Manager | Shares | Change |
|---|---|---|
| Nantahala Capital Management, LLC 0.03% of their portfolio | 148.2k $385.2k | Unchanged |
| Bleichroeder LP 0.04% of their portfolio | 68.8k $178.8k | Unchanged |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 12.5k $33.0k | Reduced -12.3k |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 2.0k $5.2k | Added +1.8k |
| FMR LLC 0.00% of their portfolio | 301 $792 | New |
| BlackRock, Inc. 0.00% of their portfolio | 122 $317 | Unchanged |
| SBI Securities Co., Ltd. 0.00% of their portfolio | 75 $195 | Unchanged |
| MORGAN STANLEY 0.00% of their portfolio | 64 $166 | Unchanged |
| NewEdge Advisors, LLC 0.00% of their portfolio | 17 $44 | Unchanged |
| BANK OF AMERICA CORP /DE/ 0.00% of their portfolio | 10 $26 | Added +1 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. — of their portfolio | 0 $0 | Unchanged |